The intranasal nano-vaccine was developed by a research group from Wuhan Institute of Virology of China announced that they have developed a new type of flu vaccine using nano-technology.
The intranasal nano-vaccine can target broad-spectrum flu viruses and induces robust immune responses, Cui Zongqiang, leader of the research group said.
"In our study, an intranasal nano-vaccine worked well against infections of H1N1 and H9N2 virus in mice," Cui said.
"The results suggest that the 3M2e-rHF nanoparticle is a promising, needle-free, intranasal administered, cross-protective influenza vaccine," he was quoted as saying by state-run Xinhua news agency.
Experts said flu infections this winter are 71 per cent above the average for the same period in the previous three years, with child cases rising sharply.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
